Key facts
- This page summarizes James Wilbur's Form 4 filing for 10x Genomics, Inc. (TXG).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 27 Nov 2023, 18:18.
James Wilbur - 22 Nov 2023 Form 4 Insider Report for 10x Genomics, Inc. (TXG)
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- TXG
- Reported as of
- 22 Nov 2023
- Net transaction value
- -$150,118
- SEC form
- 4
- Accepted by SEC
- 27 Nov 2023, 18:18:31 UTC
- Prior SEC filing
- 22 Nov 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Eric S. Whitaker, as Attorney-in-Fact for James Wilbur
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
James Wilbur filed Form 4 for 10x Genomics, Inc. (TXG) on 27 Nov 2023.
Change
- Previous filing in this sequence was filed on 22 Nov 2023.
- Current net transaction value: -$150,118.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TXG
transaction
Class A Common Stock
Sale
- Transaction value
- $150,118
- Shares
- -3,464
- Change %
- -4%
- Price
- $43.34
- Shares after
- 83,342
- Date
- 22 Nov 2023
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.